Pharmaceutical & BioScience Society, PBSS

Symposium

[In-Person] Advances in Cancer Therapeutics

Speakers: Alex Cacovean (Biomea Fusion), Eric Blouin, (Ipsos), Umer Raffat (Evercore), Amar Patel (BMS), Kelsey Gauthier (Arcus), Allison Roberts (Frontier Medicines), Jennifer Low (23andMe), Shiva Bhowmik (Trio Pharmaceuticals), Dirk Brockstedt (RAPT Therapeutics), Dara L. Burdette (Tempest Therapeutics), Cheng Liu (Eureka Therapeutics)
Organizers: Toby Freedman (Synapsis Search Recruiting and Author), Joe Carlino (Carlino Consulting), Donald McCarthy (Samsara BioCapital), Betty Chang (Summit Therapeutics), Wenfeng Xu (Chantibody Therapeutics Inc), Snow Ge (BridgeBio Pharma), Shichang Miao (PBSS)
Date: 2023-09-21
Time: 8:45-18:30 Pacific Time
Registration fee: Regular attendees: $195; Academic/Students/Postdocs/Between Jobs: $95; Major Sponsorship: $3000; Vendor Show: $695, Happy Hour Sponsorship: $995; Lunch Sponsorship: $1250; On-site Registration:$500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (1)Fortrea CRO
Vendor show vendors registered to date: (13)Aragen; ATUM; Biocytogen Boston Corp; Correlia Biosystems Inc; Curis Decontamination Systems; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Inotiv; Meadowhawk Biolabs; PharmaBlock; Revvity; SOLVO/CRL
Registration: http://www.PBSS.org
Registration deadline:2023-09-19 (it will close sooner if the seating cap is reached)

About the Topic

This one-day symposium will discuss the latest advances in the discovery and development of cancer therapeutics from leading pharmaceutical companies and promising biotech companies.

Presenting Companies / Speakers:

Bristol Myers Squibb-Amar Patel, MD, Senior Director, Early Clinical Development: Advancing Novel Modalities for the Treatment of Hematologic Cancers
Arcus-Kelsey Gauthier, PhD, Director of Biology: Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells.
Biomea Fusion-Alex Cacovean, MD, VP, Clinical Development: First-in-Class Covalent MENIN Inhibitors for AML.
Evercore ISI-Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director: ASCO Highlights.
Ipsos Healthcare-Eric Blouin, SVP of Oncology: New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective
Frontier Medicines-Allison Roberts, PhD, Senior Scientist,Chemical Biology: Challenging Cancer with Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor.
23andMe-Jennifer Low, MD, PhD, Head of Therapeutics Development: Developing genetically-validated drugs using 23andMe's genetic database.
Trio Pharmaceuticals-Shiva Bhowmik, PhD, founder nad COO: Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity.
RAPT Therapeutics-Dirk Brockstedt, PhD, Chief Scientific Officer: CCR4 oncology program update
Tempest Therapeutics-Dara L. Burdette, PhD, Executive Director: Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies
Eureka Therapeutics-Cheng Liu, PhD, Founder, President and CEO: Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR)

Morning Sessions:

Time (PT)	Topic
8:45-9:00 am	PBSS Welcome and Symposium Overview, Shichang Miao (PBSS)
9:00-9:35 am	1. Fc-Silent Anti-TIGIT Potentiates Anti-Tumor Immunity Without Depleting Regulatory T-Cells Kelsey Gauthier, PhD, Director of Biology, Arcus Biosciences
9:35-10:10 am	2. Developing Genetically-Validated Drugs Using 23andMe’s Genetic Database Jennifer Low, MD, PhD, Head of Therapeutics Development, 23andMe
10:10-10:45 am	3. Challenging Cancer With Chemoproteomics—FMC-376, a Dual KRAS G12C Inhibitor Allison Roberts, PhD, Senior Scientist, Chemical Biology, Frontier Medicines
10:45-10:55 am	Major Sponsor’s Presentation (Fortrea CRO)
10:55-11:15 am	Break Period & Vendor Show
11:15-11:50 am	4. First-in-Class Covalent MENIN Inhibitors for AML Alex Cacovean, MD, VP, Clinical Development, Biomea Fusion
11:50-12:25 pm	5. New Regulatory Approvals for Cancer Therapeutics and Their Clinical Impact – a Commercial Perspective Eric Blouin, SVP Oncology, Ipsos Healthcare
12:25-1:15 pm	Lunch

Afternoon Sessions:

Time (PT)	Topic
1:15-1:50 pm	6. ASCO Highlights Umer Raffat, Fundamental Research Analyst, Biotech Senior Managing Director, Evercore ISI
1:50-2:25 pm	7. Novel Bispecific Antibody Drugs Eliminating Cancer Cells and Immunosuppressor Cells to Enhance Anti-Tumor Immunity Shiva Bhowmik, PhD, Founder & COO, Trio Pharmaceuticals
2:25-3:00 pm	8. Advancing Novel Modalities for the Treatment of Hematologic Cancers Amar Patel, MD, Senior Director, Early Clinical Development, Bristol Myers Squibb
3:00-3:20 pm	Break
3:20-3:55 pm	9. Updates on CCR4 Antagonists for Oncology Dirk Brockstedt, PhD, Chief Scientific Officer, RAPT Therapeutics
3:55-4:30 pm	10. Weathering the Storm: Small Molecule Inhibitors of Diverse Targets as Novel Immune Oncology Therapies Dara L. Burdette, PhD, Executive Director, Tempest Therapeutics
4:30-5:05 pm	11. Treating Solid Tumors with ARTEMIS T Cells Engineered with Antibody T-Cell Receptor (AbTCR) Cheng Liu, PhD, Founder, President and CEO, Eureka Therapeutics
5:05-5:35 pm	Panel Discussion (All Speakers)
5:35-6:30 pm	Happy Hour (sponsored by Alturas Analytics)

Other Events of PBSS-San Francisco Bay:

2023-10-06, [In-Person] Human PK and Dose Prediction for Small Molecules

2023-11-07, [Free Online] The Science and Stories of Promising Biotech Startups

2023-11-13, [In-Person] Clinical Pharmacology Across the Drug Development Continuum: Key Clinical Studies, Modeling & Simulation to Support Drug Approval and Labeling

2023-12-06, [Free Online] Artificial Intelligence and Machine Learning to Drive Therapeutic Drug Discovery & Development

2024-01-19, [In-Person] ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices